Dong-A ST Company Description

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj.

to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation; Growtropin II inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta inj.

for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab.

for use in functional dyspepsia treatment; Stillen tab. to treat gastritis; Suganon tab./Sugamet XR tab.

for type 2 diabetes mellitus; Terizidone tab to treat active pulmonary and extra-pulmonary tuberculosis; and Zydena tab.

for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery.

Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.

Dong-A ST Co., Ltd.

Country	South Korea
Founded	1932
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	1,687
CEO	Min-Young Kim

Contact Details

Address: 64 Cheonhodaero Seoul South Korea
Phone	82 2 920 8114
Website	donga-st.com

Stock Details

Ticker Symbol	170900
Exchange	Korea Stock Exchange
Fiscal Year	January - December
Reporting Currency	KRW
ISIN Number	KR7170900005
SIC Code	2834

Key Executives

Name	Position
Jae-Hong Park	President and Director